Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis
April W. Armstrong, Michael Siegel, Jerry Bagel, et al.
Journal of the American Academy of Dermatology (2016) Vol. 76, Iss. 2, pp. 290-298
Open Access | Times Cited: 163

Showing 1-25 of 163 citing articles:

Psoriasis
C.E.M. Griffiths, April W. Armstrong, Jóhann E. Guðjónsson, et al.
The Lancet (2021) Vol. 397, Iss. 10281, pp. 1301-1315
Closed Access | Times Cited: 1461
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Josef S Smolen, Monika Schöls, J. Braun, et al.
Annals of the Rheumatic Diseases (2017) Vol. 77, Iss. 1, pp. 3-17
Open Access | Times Cited: 616
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, et al.
The Lancet (2018) Vol. 392, Iss. 10148, pp. 650-661
Closed Access | Times Cited: 548
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Jose U. Scher, Alexis Ogdie, Joseph F. Merola, et al.
Nature Reviews Rheumatology (2019) Vol. 15, Iss. 3, pp. 153-166
Closed Access | Times Cited: 293
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
Craig A. Elmets, Neil J. Korman, Elizabeth Farley Prater, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 2, pp. 432-470
Open Access | Times Cited: 224
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
Robert Bissonnette, Thomas A. Luger, Diamant Thaçi, et al.
Journal of the European Academy of Dermatology and Venereology (2018) Vol. 32, Iss. 9, pp. 1507-1514
Open Access | Times Cited: 178
Psoriasis and suicidality: A systematic review and meta-analysis
Sanminder Singh, Catherine L. Taylor, Heather Kornmehl, et al.
Journal of the American Academy of Dermatology (2017) Vol. 77, Iss. 3, pp. 425-440.e2
Closed Access | Times Cited: 172
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies
Marjolein de Bruin‐Weller, Tilo Biedermann, Robert Bissonnette, et al.
Acta Dermato Venereologica (2021) Vol. 101, Iss. 2, pp. adv00402-adv00402
Open Access | Times Cited: 99
The TNF/IL‐23/IL‐17 axis—Head‐to‐head trials comparing different biologics in psoriasis treatment
Lisa Lynn ten Bergen, Aleksandra Petrović, Anders Krogh Aarebrot, et al.
Scandinavian Journal of Immunology (2020) Vol. 92, Iss. 4
Open Access | Times Cited: 97
Effectiveness of Online vs In-Person Care for Adults With Psoriasis
April W. Armstrong, Cindy J. Chambers, Emanual Maverakis, et al.
JAMA Network Open (2018) Vol. 1, Iss. 6, pp. e183062-e183062
Open Access | Times Cited: 95
Clinical Goals and Barriers to Effective Psoriasis Care
Bruce Strober, Joelle M. van der Walt, April W. Armstrong, et al.
Dermatology and Therapy (2018) Vol. 9, Iss. 1, pp. 5-18
Open Access | Times Cited: 84
Itch: an under‐recognized problem in psoriasis
Boni E. Elewski, Andrew Alexis, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology (2019) Vol. 33, Iss. 8, pp. 1465-1476
Closed Access | Times Cited: 78
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi, Mark S. Talamonti, Andrea Chiricozzi, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 1, pp. 235-252
Open Access | Times Cited: 57
Deep Learning Application for Effective Classification of Different Types of Psoriasis
Syeda Fatima Aijaz, Saad Jawaid Khan, Fahad Azim, et al.
Journal of Healthcare Engineering (2022) Vol. 2022, pp. 1-12
Open Access | Times Cited: 47
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
Diamant Thaçi, Bruce Strober, Kenneth B. Gordon, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 2, pp. 495-510
Open Access | Times Cited: 43
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period
Richard B. Warren, Mark Lebwohl, Diamant Thaçi, et al.
British Journal of Dermatology (2025)
Closed Access | Times Cited: 1
Growth Differentiation Factor-15: One of the Missing Links between Psoriasis and Metabolic Syndrome
E.M. Akl, Nehad A. Fouad, M Mahmoud, et al.
Indian Dermatology Online Journal (2025)
Open Access | Times Cited: 1
Psoriatic arthritis for dermatologists
Alice B. Gottlieb, Joseph F. Merola
Journal of Dermatological Treatment (2019) Vol. 31, Iss. 7, pp. 662-679
Open Access | Times Cited: 72
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Jerry Bagel, John K Nia, Peter W. Hashim, et al.
Dermatology and Therapy (2018) Vol. 8, Iss. 4, pp. 571-579
Open Access | Times Cited: 69
Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry
Bruce Strober, Jeffrey D. Greenberg, Chitra Karki, et al.
BMJ Open (2019) Vol. 9, Iss. 4, pp. e027535-e027535
Open Access | Times Cited: 67
Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial
Giuseppe Castaldo, Luca Rastrelli, Giovanna Galdo, et al.
Nutrition (2020) Vol. 74, pp. 110757-110757
Closed Access | Times Cited: 58
Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States
April W. Armstrong, Manish Patel, Chao Li, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 22
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Bruce Strober, C. Paul, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 3, pp. 486-495
Open Access | Times Cited: 21
Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey
April W. Armstrong, Barbra Bohannan, S. Mburu, et al.
Dermatology (2023) Vol. 239, Iss. 4, pp. 621-634
Open Access | Times Cited: 20
Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay
Robert J. Konrad, Richard E. Higgs, George H. Rodgers, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top